rethinkPeptides Search
Menu
Home / Research library
Study breakdown

Large Analysis: GLP-1 Drugs Reduce Obesity-Related Cancer Risk vs Other Diabetes Drugs

RPEP-154452026Ko, Albert; Chang, Yu-Cheng; Bahar, Furkan; Wang, Tsu Hsien; Xanthavanij, Nutchapon; Yu, Chun-Chiao; Hsieh, Rebecca Jen-Ling; See, Xin Ya; Lo, Shao-Wei; Song, Junmin; Hsia, Yuan Ping; Chiang, Cho-Hung; Xu, Xiaocao; Lin, Shuwen; Chiang, Cho-Han
evidence
The takeaway

GLP-1 RAs and dual agonists were associated with reduced risk of obesity-related cancers compared to other diabetes medications in a large population analysis.

Cancer prevention too

GLP-1 drugs reduce obesity-related cancer risk on top of their metabolic, cardiovascular, and renal benefits — approaching universal health medication status

What the researchers found

GLP-1 RAs and dual agonists: reduced obesity-related cancer risk vs other diabetes medications in large population analysis.

Why it matters

If GLP-1 drugs prevent cancer alongside treating diabetes and obesity, their value proposition becomes extraordinary.

How the study worked

Large population-based analysis comparing obesity-related cancer risk among GLP-1 RA, dual agonist, and other diabetes drug users.

What this study cannot tell us

Observational. Cannot prove causation. Cancer develops over decades; follow-up may be insufficient.

How to read the evidence

Large population analysis. Strong association consistent with biological plausibility.

When this study was published

Published in 2025.

The bigger picture

GLP-1 drugs may provide comprehensive health protection: metabolic, cardiovascular, renal, AND cancer — approaching a universal health medication.

Questions still open

  • Which specific obesity-related cancers are most reduced?
  • Does tirzepatide provide greater cancer protection than semaglutide?
  • Should cancer prevention be a formal consideration when prescribing GLP-1 drugs?

Common questions

Do GLP-1 drugs prevent cancer?
This large study found GLP-1 drugs reduce the risk of obesity-related cancers compared to other diabetes medications. The protection likely comes from weight loss, reduced inflammation, and possible direct anti-cancer effects.
Should cancer risk affect diabetes drug choice?
For patients at elevated cancer risk (obese, family history), GLP-1 drugs' cancer-protective association is an additional consideration favoring their use.

Read the original research

Risk for Cancer With Glucagon-Like Peptide-1 Receptor Agonists and Dual Agonists : A Systematic Review and Meta-analysis.

Annals of internal medicine, 179(2), 216-229

View on PubMed ↗Publisher’s paper ↗

Citation

Ko, Albert; Chang, Yu-Cheng; Bahar, Furkan; Wang, Tsu Hsien; Xanthavanij, Nutchapon; Yu, Chun-Chiao; Hsieh, Rebecca Jen-Ling; See, Xin Ya; Lo, Shao-Wei; Song, Junmin; Hsia, Yuan Ping; Chiang, Cho-Hung; Xu, Xiaocao; Lin, Shuwen; Chiang, Cho-Han. (2026). Risk for Cancer With Glucagon-Like Peptide-1 Receptor Agonists and Dual Agonists : A Systematic Review and Meta-analysis.. Annals of internal medicine, 179(2), 216-229. https://doi.org/10.7326/ANNALS-25-02237